Outcome of Board Meeting held on 17.01.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Trident Lifeline Ltd approved its unaudited financial results for the quarter and nine months ended 31st December 2025 at a meeting held on January 17, 2026. On a standalone basis, revenue from operations rose to Rs 2,367.09 lakhs in Q3 FY26 from Rs 1,650.88 lakhs in Q3 FY25 (up ~43%), while nine-month revenue grew to Rs 6,992.94 lakhs from Rs 4,690.69 lakhs (~49% growth). Standalone net profit for Q3 came in at Rs 401.46 lakhs versus Rs 302.76 lakhs a year ago, and nine-month PAT rose to Rs 1,207.93 lakhs from Rs 916.14 lakhs. Consolidated results showed even sharper growth, with nine-month revenue nearly doubling to Rs 8,061.05 lakhs and consolidated PAT (after minority interest) climbing to Rs 1,210.63 lakhs from Rs 792.58 lakhs. The auditor, A Bafna & Associates, issued a clean limited review report with no qualifications on both standalone and consolidated statements. The strong consolidated growth was partly aided by fresh consolidations of subsidiaries such as TLL Parenterals and Trident Mediquip.
Strong double-digit growth in both revenue and profit across standalone and consolidated numbers, backed by an unqualified auditor review, signals robust operational momentum. For shareholders, this is a clearly positive print, though part of the consolidated surge reflects new subsidiaries being folded in rather than purely organic expansion.